Alteration of immunohistochemical biomarkers between pre- and post-chemotherapy: Hormone receptors, HER2 and Ki-67

Breast Cancer

Volumn 18, Issue 2, 2011, Pages 98-102

  Kumaki, Nobue ^a   Umemura, Shinobu ^a   Tang, Xiaoyan ^a   Saito, Yuki ^a   Suzuki, Yasuhiro ^a   Tokuda, Yutaka ^a  

^a TOKAI UNIVERSITY   (Japan)

Author keywords

HER2; Hormone receptor; Immunohistochemistry; Ki 67; Neoadjuvant chemotherapy

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; BIOLOGICAL MARKER; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLYCOPROTEIN P; HORMONE RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG RESPONSE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 79956370088     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-010-0238-1     Document Type: Article

References (26)

1. N Wolmark J Wang E Mamounas J Bryant B Fisher 2001 Preoperative chemotherapy in patient with operable breast cancer: nine-years result from National Surgical Adjuvant Breast and Bowel Project B-18 J Natl Cancer Inst Monogr 30 96 102 11773300
2. A Goldhirsch WC Wood RD Gerbel AS Coates B Thürlimann HJ Senn 2007 Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann Oncol 18 1133 1144 17675394 10.1093/annonc/mdm271 1:STN:280:DC%2BD2svlvVSkuw%3D%3D (Pubitemid 47244357)
3. N Rody T Karn R Gätje K Kourtis G Minckwitz S Loibl, et al. 2006 Gene expression profile of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophosphamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures Zentralbl Gynakol 128 76 81 16673249 10.1055/s-2006-921508 1:CAS:528:DC%2BD28Xlt1Sru7k%3D
4. GL Piper NA Patel JA Patel MB Malay TB Julian 2004 Neoadjuvant chemotherapy for locally advanced breast cancer results in alternations in preoperative tumor markers Am Surg 70 1103 1106 15663054 1:STN:280: DC%2BD2M%2FjsFyhsA%3D%3D
5. S Taucher M Rudas M Gnant K Thomanek P Dubsky S Poka, et al. 2003 Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy Endocr Relat Cancer 10 91 98 12653672 10.1677/erc.0.0100091 1:CAS:528:DC%2BD3sXksVahtLc%3D (Pubitemid 36457240)
6. A Frassoldati F Adami C Banzi M Criscuolo L Piccinini V Silingardi 1997 Changes of biological features in breast cancer cells determined by primary chemotherapy Breast Cancer Res Treat 44 185 192 9266097 10.1023/A:1005875002458 1:STN:280:DyaK2svhtFSktw%3D%3D (Pubitemid 27296377)
7. V Jain M Landry EA Levine 1996 The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma Am Surg 62 162 165 8554195 1:STN:280:DyaK287ks1Gluw%3D%3D (Pubitemid 26162285)
8. H Neubauer C Gall U Vogel R Hornung D Wallwiener E Solomayer, et al. 2008 Changes in tumor biological markers during primary systemic chemotherapy (PST) Anticancer Res 28 1797 1804 18630463 (Pubitemid 351892888)
9. AL Adams I Eltoum H Krontrias W Wang DC Chhieng 2008 The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast cancer Breast J 14 141 146 18248553 10.1111/j.1524-4741.2007.00544.x (Pubitemid 351341835)
10. RJ Burcombe A Makris PI Richman FM Daley S Noble M Pittam, et al. 2005 Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer Br J Cancer 92 147 155 15611798 10.1038/sj.bjc.6602256 1:CAS:528:DC%2BD2MXhtFSjsr0%3D (Pubitemid 40188448)
11. N Arens U Bleyl R Hildenbrand 2005 HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer Virchows Arch 446 489 496 15838646 10.1007/s00428-005-1244-0 1:CAS:528:DC%2BD2MXksl2gsrY%3D (Pubitemid 40884281)
12. IF Faneyte JG Schrama JL Peterse PL Remijnse S Rodenhuis MJ Vijver 2003 Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome Br J Cancer 88 406 412 12569384 10.1038/sj.bjc.6600749 1:STN:280:DC%2BD3s%2FlvVChtA%3D%3D (Pubitemid 36308152)
13. A Bottini A Berruti A Bersiga A Brunelli MP Brizzi BD Marco, et al. 1996 Effect of neoadjuvant chemotherapy on Ki67 labeling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours Anticancer Res 16 3105 3110 8920776 1:CAS:528:DyaK28XmvVSiu7o%3D (Pubitemid 26390257)
14. SS Lo HC Wang YM Shyr WY Lui 1994 Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy? J Surg Oncol 57 94 96 7934069 10.1002/jso.2930570205 1:STN:280:DyaK2M%2FhvFOjug%3D%3D
15. RA Hawkins AL Tesdale EDC Anderson PA Levack U Chetty APM Forrest 1990 Does the oestrogen receptor concentration of a breast cancer change during systemic therapy? Br J Cancer 61 877 880 2372489 10.1038/bjc.1990.196 1:STN:280:DyaK3czitFygsw%3D%3D (Pubitemid 20196996)
16. M Kurosumi Y Takatsuka T Watanabe S Imoto H Inaji H Tsuda, et al. 2008 Histological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial J Cancer Res Clin Oncol 134 715 722 18075758 10.1007/s00432-007-0343-5 1:CAS:528:DC%2BD1cXksVKrurc%3D
17. RB Clarke IJ Laidlaw LJ Jones A Howell E Anderson 1993 Effect of tamoxifen on Ki67 labeling index in human breast tumors and its relationship to oestrogen and progesterone receptor status Br J Cancer 67 606 611 8439511 10.1038/bjc.1993.111 1:STN:280:DyaK3s7ns1OjtQ%3D%3D (Pubitemid 23077661)
18. A Gennari MP Sormani P Pronzato M Puntoni M Colozza U Pfeffer, et al. 2008 HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials J Natl Cancer Inst 100 14 20 18159072 10.1093/jnci/djm252 1:CAS:528:DC%2BD1cXit1Cku7o%3D (Pubitemid 351767337)
19. S Taucher M Rudas RM Mader M Gnant E Sporn P Dubsky, et al. 2003 Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer Breast Cancer Res Treat 82 207 213 14703068 10.1023/B:BREA.0000004378.15859.51 1:CAS:528:DC%2BD3sXptVCrurY%3D (Pubitemid 37521977)
20. B Symczek-Gargya U Krainick M Müller-Schimpfle G Mielke R Mayer K Siegmann, et al. 2002 Large-core needle biopsy for diagnosis and treatment of breast lesions Arch Gynecol Obstet 266 198 200 10.1007/s004040100245 (Pubitemid 36056592)
21. E Azambuja F Cardoso G Castro Jr M Colozza MS Mano V Durbercq, et al. 2007 Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12155 patients Br J Cancer 96 1504 1513 17453008 10.1038/sj.bjc.6603756 (Pubitemid 46762956)
22. AS Caudle AM Gonzalez-Angulo KK Hunt P Liu L Pusztai WF Symmans, et al. 2010 Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer J Clin Oncol 28 1821 1828 20231683 10.1200/JCO.2009.25.3286
23. M Colleoni G Viale A Goldhirsch 2009 Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting Breast 18 S137 S140 19914533 10.1016/S0960-9776(09)70289-9
24. M Tewari A Krishnamurthy HS Shukla 2008 Predictive markers of response to neoadjuvant chemotherapy in breast cancer Surg Oncol 17 301 311 18467090 10.1016/j.suronc.2008.03.003
25. L Assersohn J Salter TJ Powles R A'hern A Makris RK Gregory, et al. 2003 Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer Breast Cancer Res Treat 82 113 123 14692655 10.1023/B:BREA.0000003968.45511.3f 1:STN:280:DC%2BD3sngvFCqtA%3D%3D (Pubitemid 37476011)
26. Burcombe R, Wilson GD, Dowsett M, Khan I, Richman P, Daley F, et al. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Res. 2006;8:R31.